Technology appraisal guidance [TA269] Published: 12 December 2012 Last updated: 01 January 2015
1.1 Vemurafenib is recommended as an option for treating BRAF V600 mutation‑positive unresectable or metastatic melanoma only if the manufacturer provides vemurafenib with the discount agreed in the patient access scheme.